Blood protein may predict best diabetes treatment for fatty liver
NCT ID NCT07539584
First seen Apr 21, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This study looked at 130 adults with type 2 diabetes and fatty liver disease to see if a blood protein called adiponectin can help predict which diabetes medicines work best for reducing liver fat. Participants received one of three treatments (SGLT2 inhibitors, GLP-1 agonists, or both) or no drug therapy for 6 months. The goal was to understand how adiponectin levels change and if they can guide future treatment choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moscow Regional Research and Clinical Institute
Moscow, 129110, Russia
Conditions
Explore the condition pages connected to this study.